Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Autorzy:
Martin LK; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, Columbus, OH, USA. Bekaii-Saab T Serna D Monk P Clinton SK GreverMR Kraut EH
Pokaż więcej
Źródło:
Onkologie [Onkologie] 2013; Vol. 36 (11), pp. 657-60. Date of Electronic Publication: 2013 Oct 14.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.
Autorzy:
Kogure T; Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio, United States of America ; Departments of Transplantation and Cancer Biology, Mayo Clinic, Jacksonville, Florida, United States of America. Kinghorn AD Yan I Bolon B Lucas DM GreverMR Patel T
Pokaż więcej
Źródło:
PloS one [PLoS One] 2013 Sep 26; Vol. 8 (9), pp. e76136. Date of Electronic Publication: 2013 Sep 26 (Print Publication: 2013).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.
Autorzy:
Stephens DM; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Ruppert AS; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Jones JA; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Woyach J; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Maddocks K; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Jaglowski SM; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Andritsos LA; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Flynn JM; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. GreverMR; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Lozanski G; Division of Hematopathology, Department of Pathology, The Ohio State University, Columbus, OH, USA. Johnson AJ; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [3] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA. Muthusamy N; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Heerema NA; 1] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Division of Cytogenetics, Department of Pathology, The Ohio State University, Columbus, OH, USA. Byrd JC; 1] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA [2] Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [3] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2014 Jun; Vol. 28 (6), pp. 1365-8. Date of Electronic Publication: 2014 Jan 23.
Typ publikacji:
Clinical Trial; Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.
Autorzy:
Callahan KP; Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. Minhajuddin M; Division of Hematology, University of Colorado, Denver, Aurora, CO, USA. Corbett C; Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. Lagadinou ED; Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. Rossi RM; Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. Grose V; Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. Balys MM; Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. Pan L; College of Pharmacy, The Ohio State University, Columbus, OH, USA. Jacob S; Department of Chemistry, University of Rochester, Rochester, NY, USA. Frontier A; Department of Chemistry, University of Rochester, Rochester, NY, USA. GreverMR; Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Lucas DM; Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Kinghorn AD; College of Pharmacy, The Ohio State University, Columbus, OH, USA. Liesveld JL; Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. Becker MW; Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA. Jordan CT; Division of Hematology, University of Colorado, Denver, Aurora, CO, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2014 Oct; Vol. 28 (10), pp. 1960-8. Date of Electronic Publication: 2014 Feb 28.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
Autorzy:
Lucas DM; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA. Ruppert AS; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA. Lozanski G; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA. Dewald GW; b Mayo Clinic , Rochester , MN , USA. Lozanski A; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA. Claus R; c University of Freiburg Medical Center , Freiburg , Germany.; d German Cancer Research Center , Heidelberg , Germany. Plass C; d German Cancer Research Center , Heidelberg , Germany. Flinn IW; e Sarah Cannon Research Institute and Tennessee Oncology , Nashville , TN , USA. Neuberg DS; f Dana Farber Cancer Institute , Boston , MA , USA. Paietta EM; g Montefiore Medical Center , Bronx , NY , USA. Bennett JM; h University of Rochester , Rochester , NY , USA. Jelinek DF; b Mayo Clinic , Rochester , MN , USA. Gribben JG; i Barts Cancer Institute, Queen Mary University of London , London , UK. Hussein MA; j Celgene Corporation , Summit , NJ , USA. Appelbaum FR; k Fred Hutchinson Cancer Research Center , Seattle , WA , USA. Larson RA; l University of Chicago , Chicago , IL , USA. Moore DF Jr; m Cancer Center of Kansas , Wichita , KS , USA. Tallman MS; n Memorial Sloan Kettering Cancer Center , New York , NY , USA. Byrd JC; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA. GreverMR; a Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2015; Vol. 56 (11), pp. 3031-7. Date of Electronic Publication: 2015 Mar 30.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
Autorzy:
Flynn J; Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA. Jones J; Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA. Johnson AJ; 1] Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA [2] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA. Andritsos L; Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA. Maddocks K; Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA. Jaglowski S; Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA. Hessler J; Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA. GreverMR; Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA. Im E; Merck & Co., Inc., Oncology Clinical Research, Whitehouse Station, NJ, USA. Zhou H; Merck & Co., Inc., Oncology Clinical Research, Whitehouse Station, NJ, USA. Zhu Y; Merck & Co., Inc., Oncology Clinical Research, Whitehouse Station, NJ, USA. Zhang D; Merck & Co., Inc., Oncology Clinical Research, Whitehouse Station, NJ, USA. Small K; Merck & Co., Inc., Oncology Clinical Research, Whitehouse Station, NJ, USA. Bannerji R; 1] Merck & Co., Inc., Oncology Clinical Research, Whitehouse Station, NJ, USA [2] Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Byrd JC; 1] Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA [2] Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Jul; Vol. 29 (7), pp. 1524-9. Date of Electronic Publication: 2015 Feb 24.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
Autorzy:
Andritsos LA; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Grieselhuber NR; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Anghelina M; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Rogers KA; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Roychowdhury S; b Division of Medical Oncology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Reeser JW; b Division of Medical Oncology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Timmers CD; b Division of Medical Oncology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Freud AG; c Department of Pathology , The Ohio State University , Columbus , OH , USA. Blachly JS; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Lucas DM; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Lozanski G; c Department of Pathology , The Ohio State University , Columbus , OH , USA. Jones JA; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Williams K; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Oakes C; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA. Jones D; c Department of Pathology , The Ohio State University , Columbus , OH , USA. GreverMR; a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2018 Apr; Vol. 59 (4), pp. 1008-1011. Date of Electronic Publication: 2017 Sep 18.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
